Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Steven A. Carr"'
Autor:
Meenakshi Anurag, Eric J. Jaehnig, Karsten Krug, Jonathan T. Lei, Erik J. Bergstrom, Beom-Jun Kim, Tanmayi D. Vashist, Anh Minh Tran Huynh, Yongchao Dou, Xuxu Gou, Chen Huang, Zhiao Shi, Bo Wen, Viktoriya Korchina, Richard A. Gibbs, Donna M. Muzny, Harshavardhan Doddapaneni, Lacey E. Dobrolecki, Henry Rodriguez, Ana I. Robles, Tara Hiltke, Michael T. Lewis, Julie R. Nangia, Maryam Nemati Shafaee, Shunqiang Li, Ian S. Hagemann, Jeremy Hoog, Bora Lim, C. Kent Osborne, D.R. Mani, Michael A. Gillette, Bing Zhang, Gloria V. Echeverria, George Miles, Mothaffar F. Rimawi, Steven A. Carr, Foluso O. Ademuyiwa, Shankha Satpathy, Matthew J. Ellis
Publikováno v:
Cancer Discovery. 12:2586-2605
Microscaled proteogenomics was deployed to probe the molecular basis for differential response to neoadjuvant carboplatin and docetaxel combination chemotherapy for triple-negative breast cancer (TNBC). Proteomic analyses of pretreatment patient biop
Autor:
Lisa D. Cervia, Tsukasa Shibue, Ashir A. Borah, Benjamin Gaeta, Linh He, Lisa Leung, Naomi Li, Sydney M. Moyer, Brian H. Shim, Nancy Dumont, Alfredo Gonzalez, Nolan R. Bick, Mariya Kazachkova, Joshua M. Dempster, John Michael Krill-Burger, Federica Piccioni, Namrata D. Udeshi, Meagan E. Olive, Steven A. Carr, David E. Root, James M. McFarland, Francisca Vazquez, William C. Hahn
Publikováno v:
Cancer discovery.
Systematic identification of signaling pathways required for the fitness of cancer cells will facilitate the development of new cancer therapies. We used gene essentiality measurements in 1,086 cancer cell lines to identify selective coessentiality m
Autor:
Christopher R. Kinsinger, Matthew J. Ellis, Karin Rodland, Henry Rodriguez, Raymond R. Townsend, Amanda G. Paulovich, Steven A. Carr, Richard D. Smith, Michael A. Gillette, Daniel C. Liebler, Mehdi Mesri
Publikováno v:
Cancer discovery. 3(10)
Summary: The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium is applying the latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome Atlas (TCGA) program, a joint initiative of t